The deals will make medications such as Wegovy and Zepbound far cheaper and open access to millions of Americans who could not afford them before.
The administration said the move will give people affordable options for drugs that have been expensive, difficult to access, and often not covered by insurance.
The deal will make starting doses of Wegovy, Ozempic, Zepbound, and other obesity treatments available at steep discounts through a new program called TrumpRx.
According to Novo Nordisk, the lowest dose of Wegovy will cost $149 per month if approved. The pricing will apply to the company’s direct-to-patient platform and will also extend to Medicare Part D, Medicaid, and self-pay programs. Novo Nordisk said it expects to announce additional price reductions for Wegovy and Ozempic in the coming weeks.
Trump called the agreement a victory for patients. He said it will save lives and help millions of Americans struggling with obesity and diabetes access drugs that were previously out of reach.
Eli Lilly will offer Zepbound through its digital pharmacy platform, LillyDirect, starting at $299 for the lowest dose and $449 for higher doses. That is about $50 below the current direct-to-patient price and comparable to pricing in Europe.
Another drug awaiting federal approval, Orforglipron, will also start at $149 for the lowest dose. The company will add medicines like Emgality, Trulicity, and Mounjaro to LillyDirect at price cuts of up to 60 percent.
A senior administration official said Americans have been paying as much as 520 percent more than Europeans for Zepbound and up to 1,400 percent more for Wegovy. Under the new agreement, direct-pay customers will pay an average of $350 per month for all doses, with that amount falling to $245 over two years.
The policy also expands Medicare access. For the first time, Medicare will cover these drugs for weight loss under certain medical conditions. Medicare patients will not pay more than a $50 monthly copay. The discounted price for the government program will be $149 for initial oral doses and $245 for all other doses.
Medicaid programs will have the option to participate, and states that opt in will also receive lower prices. The White House said the change could save Medicare about $300 billion by reducing long-term health care costs linked to obesity.
More than 16 million Americans have used Wegovy, Zepbound, or similar GLP-1 drugs. These medications help regulate appetite, increase feelings of fullness, and improve blood sugar control. They were originally created to treat type 2 diabetes but are now FDA-approved for weight loss under brands such as Wegovy and Zepbound.
For years, patients have struggled to get these drugs because of insurance limits, high cash prices, and supply shortages. Some people turned to Ozempic or Mounjaro off-label after demand exploded nationwide.
Both companies told FOX Business they have been working with the administration on more affordable access and support the Most Favored Nation plan, which aims to bring U.S. drug prices in line with other developed countries.
The new program will also require Eli Lilly and Novo Nordisk to provide lifestyle coaching and nutrition guidance for patients using the medication. Commercial insurers will be able to negotiate lower prices as well.
Officials said the discount program for direct-pay customers will begin in January. Medicare and Medicaid price cuts will begin in July. Expanded Medicare coverage for weight-loss use will start in 2026. Future GLP-1 drugs from either company will also be sold at reduced prices if approved for obesity.
Trump said the deals represent a major victory for American families and will help people live longer, healthier lives without being crushed by soaring drug costs.